Pharmafile Logo

fast track appraisal

- PMLiVE

PMCPA ‘appalled’ by Chiesi’s Code of Practice breach

Ethics watchdog says firm mislead it in a "completely unacceptable" manner

National Institute for Health and Care Excellence NICE logo

Patients should have a say in their medication, claims NICE

Also states health practitioners should be able to share information

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Boehringer in breach over beer drinking, lederhosen presentation

German firm earns PMCPA’s wrath over ‘inappropriate’ conference speakers

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

National Institute for Health and Care Excellence NICE logo

NICE sets out approach to stop antimicrobial resistance

Guidelines call for formation of stewardship programmes

- PMLiVE

UK CROs to offer drug discovery services to Nordic businesses

Will head to Copenhagen in March for market visit

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links